APO-RIVASTIGMINE CAPSULE

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE)

থেকে পাওয়া:

APOTEX INC

এটিসি কোড:

N06DA03

INN (আন্তর্জাতিক নাম):

RIVASTIGMINE

ডোজ:

3MG

ফার্মাসিউটিকাল ফর্ম:

CAPSULE

রচনা:

RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 3MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

100

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0140521002; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2009-11-04

পণ্য বৈশিষ্ট্য

Page 1 of 53
PRODUCT MONOGRAPH
PR APO-RIVASTIGMINE
1.5 MG, 3 MG, 4.5 MG AND 6 MG RIVASTIGMINE
(AS RIVASTIGMINE HYDROGEN TARTRATE)
CAPSULES USP
CHOLINESTERASE INHIBITOR
APOTEX INC.
DATE OF REVISION:
150 SIGNET DRIVE
TORONTO, ONTARIO MAY 12, 2015
M9L 1T9
CONTROL NO. 184244
Page 2 of 53
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
3
SUMMARY PRODUCT INFORMATION
...........................................................................................
3
INDICATIONS AND CLINICAL USE
.................................................................................................
3
CONTRAINDICATIONS
......................................................................................................................
3
WARNINGS AND PRECAUTIONS
.....................................................................................................
4
ADVERSE REACTIONS
....................................................................................................................
10
DRUG INTERACTIONS
.....................................................................................................................
25
DOSAGE AND ADMINISTRATION
.................................................................................................
26
OVERDOSAGE
...................................................................................................................................
28
ACTION AND CLINICAL PHARMACOLOGY
...............................................................................
29
STORAGE AND STABILITY
.............................................................................................................
32
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................................ 32
PART II: SCIENTIFIC INFORMATION
...........................................................................................
33
PHARMACEUTICAL INFORMATION
...................................................